Lv11
40 积分 2023-09-07 加入
Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study
4小时前
已完结
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure
6天前
已完结
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial
12天前
已完结
Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study
13天前
已完结
Comparison of coronary atherosclerotic features in response to achieving LDL-C <55 mg/dl between non-diabetic and diabetic patients: insights from the REASSURE-NIRS registry
2个月前
已完结
Management of diabetic dyslipidemia: Navigating the new American and European Guidelines
2个月前
已完结
Residual cardiovascular risk: When should we treat it?
2个月前
已完结
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
7个月前
已完结
An update on pharmacotherapies in diabetic dyslipidemia
7个月前
已完结
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
7个月前
已关闭
皖公网安备34019202002308
